The Biggest Psychedelic News Stories of the Week - September 11th

The Biggest Psychedelic News Stories of the Week – September 11th

, ,
California stands on the cusp of a psychedelic revolution with the TREAT Act and a landmark bill on 'magic mushrooms,' even as Michigan, Congress, and global initiatives from Sweden to Canada expand the horizons of mental health, addiction treatment, and veteran care.
/6-of-the-best-psilocybin-retreats-in-jamaica-february-2023/

MDMA Successfully Treats PTSD in Another Phase 3 Trial Sponsored by MAPS

,
"MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024," says MAPS founder and president Rick Doblin.
The Millennium’s Primer Series: Neuroinflammation as a Barrier to the Success of Psychedelic-Assisted Therapies

The Millennium’s Primer Series: Neuroinflammation as a Barrier to the Success of Psychedelic-Assisted Therapies

,
Initial clinical trials into this exciting frontier have unveiled promising outcomes, showcasing remarkable improvements in clinical results using anti-inflammatory, nanoliposomal products prior to the application of a psychedelic agent.
The Risks of Mixing Psychedelics and Opioids for Chronic Pain

The Risks of Mixing Psychedelics and Opioids for Chronic Pain

The main risk of mixing psychedelics and opioids for chronic pain is an opioid overdose—a potentially life-threatening condition that should be treated as quickly as possible. Otherwise, it may result in coma, brain damage, and death.
First Psilocybin-Assisted Addiction Recovery Program in U.S. Opens in Oregon

First Psilocybin-Assisted Addiction Recovery Program in U.S. Opens in Oregon

Oregon pioneers the first Psilocybin-Assisted Addiction Recovery Program in the United States.
From Risk to Resilience: Preparing Healthcare Providers for the Psychedelic Therapy Revolution

From Risk to Resilience: Healthcare Providers and the Psychedelic Therapy Revolution

Currently, MDMA-assisted therapy for PTSD and psilocybin for depression disorders await approval from the FDA. Meanwhile, practitioners are creating spaces to give their patients this revolutionary experience. 
Yet Another Study Determines Psilocybin Provides 'Rapid and Sustained Anti-Depressant Effect'

New Study Determines Psilocybin Provides ‘Rapid and Sustained Antidepressant Effect’

,
One of the largest studies yet lends more evidence to the view that psilocybin "may hold promise as a novel intervention for major depressive disorder."
30 Days, 30 Psychedelic Retreats - Lessons Learned From Our Quest to Study Central American Retreats and Their Potential to Heal Minds

30 Days, 30 Psychedelic Retreats – Lessons Learned From Our Quest to Study Central American Retreats and Their Potential to Heal Minds

,
My journey through 30 retreats made it quite clear that every center has a somewhat unique philosophy of care. With much of the science still early and murky, it’s difficult to say that one approach is better or worse than any others.
Psychedelic-Therapy As Employee Health Benefit is Becoming Possible and the First Results Are In

Psychedelic Therapy As Employee Health Benefit Is Becoming Possible and the First Results Are In

No fewer than 50 companies have shown interest in offering psychedelic therapy to their employees through healthcare plan startup Enthea.

First-Ever Professional Guidelines for Psychedelic-Assisted Therapy Practitioners Now Published by APPA and BrainFutures

The first-ever set of professional practice guidelines for psychedelic-assisted therapy were officially published today.